



Annual report and financial statements

31 March 2015

Registered Charity No: 1070618
Registered Company No: 3520281

Contents

Mission	3
Administrative details	4
Report of the Council	6
Aims and objectives	6
Promoting excellence	7
Influencing policy to improve health and wealth	9
Nurturing the next generation of medical researchers	11
Linking academia, industry and the NHS	13
Seizing international opportunities	15
Encouraging dialogue about medical sciences	17
Governance	19
Financial Review	21
Statement of Trustees' responsibilities	24
Independent auditor's report	25
Consolidated statement of financial activities	27
Balance sheets	28
Notes to the financial statements	29

Mission

The Academy of Medical Sciences is an independent organisation that represents the spectrum of medical science – from basic research through clinical application to healthcare delivery. Our mission is to achieve better healthcare through the application of research to the practice of medicine.

We achieve this by:

- Providing expert, evidence-based information and advice to policymakers
- Supporting the development of a first class medical science workforce
- Championing the UK's medical research strengths in academia, in the NHS and in the biotechnology and pharmaceutical industries.

Our elected Fellows are central to our success. It is their unique diversity of talent, collective experience and professionalism that enables the Academy to address complex issues of science and healthcare with expertise and authority. In this way, the Fellowship is a national, public resource of independent and expert advice on medical science and healthcare.

Administrative details

Name of charity: The Academy of Medical Sciences

Registered charity no: 1070618

Registered company no: 3520281

Principal address: 41 Portland Place
(and Registered Office) London, W1B 1QH

Principal bankers: Lloyds Bank PLC
8-10 Waterloo Place
London, SW1Y 4BE

Auditors: BDO LLP
55 Baker Street
London, W1U 7EU

Investment fund manager: Sarasin & Partners LLP
Juxon House
100 St Paul's Churchyard
London, EC4M 8BU

Honorary Officers of the Academy of Medical Sciences

President: Professor Sir John Tooke PMedSci
Vice Provost (Health), University College London

Vice-President: Professor Martin Humphries FMedSci
Vice-President & Dean, Faculty of Life Sciences, University of Manchester

Vice-President: Professor Sir Patrick Sissons FMedSci (until December 2014)
Emeritus Regius Professor of Physic, University of Cambridge
Professor Christopher Day FMedSci (from December 2014)
Pro-Vice Chancellor, Newcastle University

Treasurer: Professor Susan Iversen CBE FMedSci (until December 2014)
Emeritus Professor of Psychology, University of Oxford
Professor Anne Dell CBE FRS FMedSci (from December 2014)
Professor of Carbohydrate Biochemistry, Imperial College London

Registrar: Professor Moira Whyte OBE FMedSci
Professor of Adult Respiratory Medicine, University of Edinburgh

Foreign Secretary: Professor George Griffin FMedSci
Centre for Infection, St George's University of London

Ordinary Members of Council

Professor Jonathan Ashmore FRS FMedSci	appointed December 2014
Sir Alasdair Breckenridge CBE FRSE FMedSci	
Professor Edwin Chilvers FMedSci	
Professor Carol Dezateux CBE FMedSci	retired December 2014
Professor Stephen Dunnett FMedSci	
Professor Maria Fitzgerald FMedSci	
Professor Jayne Franklyn FMedSci	retired December 2014
Professor Graham Hart FMedSci	
Professor John Iredale FMedSci	retired December 2014
Professor Fiona Karet FMedSci	
Professor Andrew Lees FMedSci	
Professor Roger Lemon FMedSci	retired December 2014
Professor Jane Norman FMedSci	appointed December 2014
Professor Sir Michael Owen FMedSci FLSW	appointed December 2014
Sir Michael Rawlins	appointed December 2014
Professor Jonathan Shepherd CBE FMedSci	retired December 2014
Professor Simon Tavaré FRS FMedSci	retired December 2014
Professor Veronica van Heyningen CBE FRS FRSE FMedSci	
Professor Peter Weissberg FMedSci	

Co-opted members 2014

Professor Anna Dominiczak FMedSci	retired December 2014
Professor Shitij Kapur FMedSci	retired December 2014
Professor Deborah Lawlor FMedSci	appointed December 2014
Dr Melanie Lee CBE FMedSci	re-appointed December 2014
Professor David Mant OBE FMedSci	appointed December 2014
Professor Teresa Marteau FMedSci	appointed December 2014
Professor Christopher Pugh FMedSci	appointed December 2014

Principal Employed Officers

Executive Director	Dr Helen Munn
Director of Biomedical Grants and Careers Policy	Dr Suzanne Candy
Director of Communications	Mr Nick Hillier
Director of Medical Science Policy	Dr Rachel Quinn
Director of Finance and Resources	Mrs Chris Straw

Aims and objectives

Our 1998 Memorandum and Articles of Association set out the Academy's four objects: to promote excellence in medical research and in the teaching of medical sciences; to promote the application of research to the practice of medicine and to the advancement of human health and welfare; to promote public understanding of the medical sciences and their impact on society; and to assess issues of medical science of concern to the public and to disseminate the results of such assessment.

The objects are delivered under the Academy's six priority programmes, as set out in our 2012-2016 Strategic Plan:

1. Promoting excellence
2. Influencing policy to improve health and wealth
3. Nurturing the next generation of medical researchers
4. Linking academia, industry and the NHS
5. Seizing international opportunities
6. Encouraging dialogue about medical science

In delivering our strategy we will:

- Demonstrate to decision makers through the information and advice we provide:
 - The advantages of evidence-based health policy.
 - How the UK and the EU can remain a supportive environment for excellent medical research and researchers.
 - The ways to maximise the translation of the knowledge generated for public good.
- Strengthen connections with the medical research ecosystem and the building of mutual recognition that industry, academia and the NHS are credible and crucial partners in delivering healthcare benefits to society.
- Inspire, and nurture excellence in, the next generation of medical science researchers, ensuring that they can maximise scientific discoveries for health and wealth benefits.
- Position the Academy as a receptive, innovative and future-orientated organisation with an engaged Fellowship that reflects the diversity of the life sciences sector.

Promoting excellence

Strategic aims

The heart of the Academy of Medical Sciences is our Fellowship – over 1100 of the most eminent UK researchers who have made transformative contributions to medical science. The excellence of the Fellows' science, their contribution to medicine and society and the range of their achievements are reflected throughout the Academy's work. Through our prize lectures, awards and election of Fellows, we seek to recognise the best talent in medical science – in all its diverse forms - and to champion new knowledge and its translation into patient benefits.

Significant activities

- **Recognising outstanding individuals.** Our annual election of Fellows continues to be the cornerstone of our work, enabling us to maintain a unique, national resource of medical science talent, utilised by the Academy to drive research and innovation for the benefit of patients and society. FMedSci is internationally recognised as a mark of esteem and achievement in medical science. In July 2014 we admitted 44 new Fellows, who represent the UK's leaders in medical research and healthcare.
- **Improving diversity in the Fellowship.** The Fellowship Committee and Sectional Committees continued to review diversity – in all its forms - amongst the candidates and elected Fellows. In 2014, 34% of newly elected Fellows were women. This year we initiated an Industry Reference Group to support the assessment of candidates for Fellowship whose careers have been spent working in industry. This group will identify up to 4 industry candidates for election to the Academy in 2015.
- **Modernising our Fellowship election system.** Thanks to a generous gift from The Royal Society, we have been developing a new online system to support our Fellowship election that will streamline the process and provide a more user-friendly interface for nominators, reviewers and Sectional Committee members. The system will go live for the 2016 election cycle.
- **Engaging the Fellowship and beyond.** In 2014 we established a network of 10 Fellows to serve as regional champions across the UK. Champions have undertaken a wider range of activities to increase connectivity amongst Fellows, raise awareness of the Academy's work amongst the broader biomedical community, and facilitate engagement between the Academy and the Fellowship.
- **Promoting scientific debate.** Our Fellows' discussion dinners continued to be a popular programme with five events taking place over the course of the year. Topics included: obesity and the skeleton, improved treatment of acute leukaemia, point of care genetics, and population physiology in the "-omics" era. A regional Fellows' dinner was held in Birmingham with a talk given by Professor Sir John Bell GBE FRS HonFREng FMedSci.
- **Celebrating medical science.** Our named lectures provide opportunities to celebrate outstanding achievements in medical science and to highlight major scientific breakthroughs. In July 2014 the Raymond and Beverly Sackler Distinguished Lecture in the Medical Sciences was given in London and Cambridge by Professor Dario Alessi FRS FRSE FMedSci on *Disruptions on the Highways of Cell Communications*. In December 2014 the Jean Shanks Lecture was given by

Professor Fiona Powrie FRS FMedSci on *Dining out with friends: The intestinal microbiome in health and disease*. Each lecture was filmed and made available on our Youtube channel allowing hundreds of views.

- **Recognising excellence at all career stages.** The Academy's *Lancet Prize*, which recognises a postdoctoral clinical academic trainee for excellence in research, was awarded to Dr Myles Lewis, Clinician Scientist Fellow, Queen Mary University of London. The Lord Leonard and Lady Estelle Wolfson Prize was awarded for the first time at the Spring Meeting for Clinician Scientist in Training to Dr Svetlana Reilly, Oxford University. At the Academy's Winter Science meeting in November 2014 our prize for excellence in communicating research was awarded to Dr Kate Baker, University of Cambridge.

Future plans

- **Improving diversity in the Fellowship.** We will continue to build a Fellowship that fully represents excellence in medical science irrespective of gender, age, ethnicity, discipline, geographical location or workplace. Our Industry Reference Group will continue to work to improve industry representation amongst candidates and elected Fellows.
- **Implementing an electronic election system.** All candidates for the 2016 Fellowship Election will be submitted and administered through eLect2, the Academy's new electronic election system. This system will streamline the process and create a user friendly interface for Fellows to follow the process of their candidates through the nomination and assessment phases of the election.
- **Engaging the Fellowship and beyond.** We will capitalise on the recent activities of our 10 Regional Champions to build a stronger connection amongst our Fellows and their local communities. Champions will work in their region to: increase connectivity amongst Fellows; raise awareness of the Academy's work amongst the broader biomedical community; and facilitate engagement between the Academy and the Fellowship.
- **Championing knowledge.** We will continue to build the reputation of our prestigious annual lectures and prizes, and increase their reach through our website and online tools.

Influencing policy to improve health and wealth

Strategic aims

One of the Academy's greatest strengths is our ability to convene the best medical scientists to address some of the most significant challenges facing society. We aim to be the UK's leading source of independent advice for those making decisions about medical research and to provide evidence from medical science to underpin policy development in the public, private and charitable sectors. As outlined in our Strategy, our key themes are: tackling major challenges; maximising our impact; engaging policymakers; and looking ahead. With the Fellowship at the core, we have continued to set, and respond to, the policy agenda.

Significant activities

- **Health of the Public 2040.** In November 2014 we launched our major Working Group project, *Health of the Public in 2040*, chaired by Dame Anne Johnson FMedSci. This study aims to identify the main health challenges the UK public is likely to face in 2040 and opportunities for mitigation/improvement. The project will inform strategies and recommendations — in terms of research evidence, capacity, infrastructure and the mechanisms for translating research into practice — in health and related areas. A multi-disciplinary horizon scanning workshop was held in November, followed by a call for written input issued in March 2015.
- **Treating influenza.** Following a request from the Department of Health we launched a Steering Group project to consider the outcomes of research on the use of antivirals in seasonal and pandemic influenza. The Group is also considering emerging treatments for influenza and research priorities. This project, conducted jointly with the Wellcome Trust, included a one-day evidence-gathering workshop in February 2015.
- **Securing a sustainable science and innovation base.** This continued to be a major strand of Academy policy activity. In June 2014 we published the results of a study commissioned jointly with the Department of Health, Wellcome Trust and Cancer Research UK on the economic benefits of cancer-related research. We provided a joint submission with the other National Academies to BIS consultations on priorities for the capital budget and the Science and Innovation Strategy. We were represented on the Ministerial Advisory Group for both of these initiatives. In February 2015 we published a pre-election statement '*Building a stronger future*', which set out the Academies' priorities for an incoming Government with regard to research, innovation and growth. The launch was accompanied by a dinner with senior stakeholders and a press conference.
- **Ensuring appropriate regulation around laboratory animals.** Working closely with the UK Biosciences Sector Coalition, we have influenced the work of the Home Office relating to the release of data about the use of animals in research and the Code of Practice to accompany the revised Animals (Scientific Procedures) Act. We also continued our liaison with the Home Office with regard to Guidance on the Use of Human Material in Animals, following a recommendation of our 2011 report on '*Animals containing human material*'.

- **Promoting engagement with policy makers.** As part of the All Party Parliamentary Group on Medical Research, we connected our Fellows and other senior researchers with Parliamentarians on topics including stem cells, patients and economic growth, and the use of personal data. The Academy also contributed to legislative briefings, Parliamentary Select Committee inquiries and government consultations on topics including: the Medical Innovation Bill; the internationalisation of the Research Excellence Framework and mitochondrial donation. We held very successful fringe events with the other Academies at the three main Party Conferences. Our competitive three month policy internship schemes funded by MRC and the Wellcome Trust continue to train a new generation of researchers who are confident in engaging in policy debates, with six interns graduating from the scheme in 2014-5.
- **Maximising the impact of our policy work.** Following up recommendations of previous reports is an explicit commitment in the 2012-16 strategy. In 2014-5 we engaged successfully with decision makers in Government and elsewhere to implement recommendations from previous reports on animals containing human material, stratified medicine and the regulation and governance of health research.

Future plans

- **Social contract around medical innovation.** Beginning with an initial scoping workshop held jointly with the British Academy, we will launch a new work stream to consider a new social contract to realise the benefits of innovations in medical science. This project will examine the perceptions of risk and value by individuals, organisations and society.
- **Evaluating evidence.** Following a direct request from the Chief Medical Officer for England, we will consider how the Academy can contribute to debates about assessments of drug safety and efficacy, including with regard to statin therapy for cardiovascular disease.
- **Reproducibility and reliability of biomedical research.** Following concerns about the robustness of medical science outputs expressed in the specialist and mainstream media, we will hold a major international symposium on this topic with the Wellcome Trust, MRC and BBSRC, and consider the implications of discussions for the sponsors and other key stakeholders.
- **Reports of *Health of the Public 2040* and *Treating influenza* projects.** We will launch the reports of these projects and seek opportunities to engage with stakeholders to implement their recommendations and conclusions.
- **Ensuring an effective science and innovation landscape.** Working with the other National Academies and the wider biomedical community we will focus on: engaging with the incoming Government; influencing the next spending review; and contributing to the reviews of the Research Councils and business-university collaborations.
- **Following up policy reports.** We will continue to exploit opportunities to bring the recommendations of our previous reports to the attention of relevant decision makers.

Nurturing the next generation of medical researchers

Strategic aims

The Academy is an authoritative voice on the development of sustainable training and career pathways in medical research, and a source of inspiration, information and personal support for researchers. We provide direct financial support to early career researchers through our funding schemes. Our aims under this objective include networking researchers across boundaries, fostering research independence and remaining connected. Key to the success of these aims is the support and work of the Fellowship. Academy Fellows act as mentors and speakers at events, as well as serving as reviewers and panel members for our grants schemes.

Significant activities

- **Maintaining our innovative grant support schemes.** Our funding schemes target key points in the clinical academic training pathway to encourage career development. Schemes are run in partnership with other funders, leveraging considerable financial resource and allowing us to support the full spectrum of clinical research. Our successful **Starter Grants for Clinical Lecturers** scheme continued to attract very high quality applications, with 48 awards made in 2014-5 at a total investment of £1,358,754. The latest round of our esteemed **Clinician Scientist Fellowship (CSF)** scheme is supported by £4 million funding from The Health Foundation. During the year, all five of the new cohort of CSFs started their fellowships and £543,897 grant funding was received by the Academy as a result. Further details on the grants schemes can be found in the Notes to the Accounts.
- **Monitoring the impact of our grants portfolio.** The Academy has adopted Researchfish, a research outcomes system that allows grant holders to track and report the outcomes of all their research. Our first submission year in 2014 generated 100% compliance on the 143 live awards, reporting 337 publications and nearly £20 million in follow on funding, i.e every £1 of Starter Grant funding has enabled awardees to leverage an additional £4.42 of follow-on funding.
- **Delivering mentoring and careers support, and catalysing other organisations to develop and deliver complementary schemes.** We were successful in renewing support for our acclaimed mentoring and careers development scheme for aspiring clinical researchers from NIHR, NISCHR and GSK in 2014. With support from MRC, we expanded this programme to include a cohort of early career non-clinical researchers – a key strategic priority previously identified by Council. Our ‘catalytic workshops’ were successful in engaging a range of organisations to scope the potential for their own mentoring schemes and we supported NIHR Biomedical Research Unit and Biomedical Research Centre staff to establish their own mentoring programmes.
- **Inspiring medical and dental students with research.** The INSPIRE scheme supported nine innovative projects through the Special Project Fund in 2014-5 and made 21 awards through the second round of small grant funding. The scheme is proving successful in meeting its aims and linking medical schools and other stakeholders to share best practice and collaborate to deliver activities to engage medical and dental students with research - as evidenced by the number of high quality consortium applications received.

- **Launching a pilot programme to support women in research.** The Academy has launched SUSTAIN, a pilot scheme to support 20 women at the cusp of research independence. Working with the MRC, Royal Society and Royal College of Physicians, this year long programme will draw together women from across scientific disciplines to develop their career and leadership potential.
- **Engaging with aspiring medical researchers in the regions.** Events for early career clinical researchers were held in Birmingham, Edinburgh, Leeds, London, Manchester and Newcastle in 2014-5. These events enabled hundreds of attendees to network with peers and senior colleagues, gain skills in communication and grantsmanship, and develop a better understanding of career pathways.
- **Providing a hub for scientific debate.** Our two annual scientific meetings for aspiring clinical academics continue to grow in popularity. The Spring Meeting for Clinician Scientists in Training, supported by a prestigious partnership with *The Lancet*, was held in February 2015 and attended by HRH The Princess Royal. Our Winter Science Meeting for Starter Grant Holders was held in November 2014 and attracted a large and engaged audience of awardees, Fellows and funders.
- **Influencing academic careers and training policies.** Our major working group project on '*Team Science*' is looking at the incentives and barriers to early career researchers participating in large collaborative projects and will be published in late 2015. Our Careers Committee monitors opportunities and challenges in medical research career pathways, including ongoing changes in the NHS. We have continued to engage with the Shape of Medical Training Review, including holding a joint workshop with Medical Schools Council to discuss the needs of clinical academics and ensuring academic representation on key decision committees.

Future plans

- We will **ensure successful delivery of the SUSTAIN pilot scheme**, including ensuring robust monitoring and evaluation. We will continue to engage a broad range of stakeholders to share learning and best practice, and to catalyse the development of further schemes.
- We will initiate **a new grants scheme for biomedical researchers transitioning to independence**. Through extensive scoping work, we have developed a blueprint for a scheme of starter grants for early career non-clinical researchers; we are working with potential funding partners to secure delivery.
- Utilising the learning from the implementation of Researchfish, we will conduct a full external **evaluation of our Starter Grants for Clinical Lecturers scheme**.
- We will consider how the Academy can work with stakeholders to continue to **inspire medical and dental students with research**, through analysis of the INSPIRE evaluation data and engagement with the community.
- We will **further develop our support for aspiring medical researchers** by producing new mentoring videos and information sheets, widening the availability of our resources, and holding a 'horizon scanning' event for current and past CSF awardees.
- We will **publish our Working Group report on 'Team Science'** and seek to ensure uptake of recommendations by the wider research community.
- We will continue to monitor and influence the implementation of the **Shape of Medical Training review**, and respond to other policy developments relating to biomedical research careers.

Linking academia, industry and the NHS

Strategic aims

Meeting patient needs through biomedical discovery in an economically and socially sustainable manner requires a holistic approach. Facilitating strong and equitable partnerships between academia, industry and the NHS, along with effective engagement with regulators, has been a major focus of the Academy's activities and underpins our FORUM. Our ability to connect researchers, research funders and users from across government, academia, industry, the charity sector and the NHS enables us to deliver our aims of: promoting sustainable models of translation; supporting a vibrant innovation ecosystem; and ensuring a strong UK life science industry.

Significant activities

- **FORUM workshops.** In 2014-5 these events brought together a range of high-level stakeholders from across the life sciences ecosystem to tackle: the challenges associated with *poor patient adherence to medicines* (co-hosted with the Faculty of Pharmaceutical Medicine); the *regulation and quality control of health apps* (co-hosted with the Royal Academy of Engineering); and how *geographical clusters* can work together effectively to drive medical research and innovation (co-hosted with the Wellcome Trust).
- **Streamlining research regulation and governance.** We continued to drive the successful implementation of our 2011 report '*A new pathway for the regulation and governance of health research*', including welcoming the introduction of the single Health Research Authority (HRA) approval for multi-site research in the NHS – a major recommendation of the report. In October, we hosted a second event for Fellows and the academic community to feed directly into the HRA's future directions and programme of work, and contributed to its consultation on simplified consent. We published the report of our FORUM event on data '*safe havens*' and continued to engage with other aspects surrounding access to patient data.
- **Future of the Life Sciences ecosystem.** In February, at the 2015 FORUM Annual Lecture, George Freeman MP (the first Minister for Life Sciences) and the UK's three Life Sciences Champions discussed the future of the life sciences ecosystem. This event followed the '*21st Century Landscape for Life Sciences*' meeting in October 2014 when the Academy and the Wellcome Trust provided an opportunity for Mr Freeman to engage with key stakeholders about the future of medical innovation.

Future plans

- Following up our 2013 working group report on **stratified medicine**, we will hold a symposium in Southampton in May 2015 to address issues for implementing stratified medicine in healthcare settings and preparing the healthcare community to embrace this approach to therapy.
- We will continue to engage with efforts to improve the **regulation and governance of health research** and seek to mark the five year anniversary of our influential report on this topic.

- Our FORUM workshops will bring together high-level representatives from across academia, industry and healthcare to tackle topics including the **challenges and opportunities of real world data** and **ageing as a risk factor for disease**. We will reconvene the representatives from the **geographical clusters** meeting in Autumn 2015.
- **FORUM activities** will be informed by an increasing number of members from across the life sciences ecosystem.
- We will support efforts to **improve the translation of medical research into patient benefit** by engaging with the Government's Accelerating Access Review.

Seizing international opportunities

Strategic aims

Medical science is an increasingly international endeavour and many major health challenges are now global in nature. The Academy strives to ensure that the UK takes a leadership role in tackling these challenges and in enabling excellent researchers to move and collaborate across national boundaries. Our key themes are: influencing European policy for health and research; responding to global health challenges; and promoting international mobility, connections and capacity building. In delivering these aims we draw on the expertise of our Fellows working in the UK and overseas and on our partnerships, particularly with our sister Academies across the world.

Significant activities

- **International research fellowships.** Our international work in 2014-15 was dominated by the initiation of two new international Fellowship schemes. These schemes are part of the Government's Newton Fund programme, established to promote the economic development and social welfare of a specified set of partner countries. The schemes introduce a valuable new dimension to the Academy's international activities. We worked with the other National Academies to establish matched funding agreements with partner organisations in Brazil (CONFAP), China (NSFC), Mexico (CONACYT) and South Africa (NRF). These agreements allowed us to:
 - Establish a scheme of **Newton Advanced Fellowships** (with the Royal Society and British Academy), to support early to mid-career international researchers to develop the strengths and capabilities of their research groups through training, collaboration and reciprocal visits with a UK partner. We awarded 10 fellowships to applicants from our four partner countries, worth a total of £1,019,650 over the next three years.
 - Launch a round of **Newton International Fellowships**, again working alongside the Royal Society and British Academy. These enable early career overseas researchers to spend two years training in the UK. A call for applications was launched in 2014-15 and we will award Fellowships for the first time in 2015-6.
- **Informing European medical science policy.** We continued our work to influence developments on European policy issues, either alone or in partnership with UK stakeholders and our European network, the Federation of European Academies of Medicine (FEAM). These issues included: the European Citizens Initiatives 'Stop vivisection' and 'One of Us'; the European Commission's plans to reallocate funding from Horizon 2020 to the European Fund for Strategic Investments (EFSI); and the provision of science advice in Europe. We also worked with the other National Academies to host a lecture by the new EU Commissioner for Research, Science and Innovation, Carlos Moedas.
- **Securing the future of research using patient data.** Working with the Wellcome Trust and FEAM we continued to alert policymakers and parliamentarians across Europe to the negative impact of amendments proposed by the European Parliament to the EU Data Protection Regulation. If passed, this legislation could hinder, or even

prevent, research that is vital to public health. This will continue to be a priority area for activity in 2015-6.

- **International Health Lecture.** Our 2014 lecture was delivered by Dr Trevor Mundel, President of the Gates Foundation Global Health Program, in April 2014. It was entitled '*A scientist, an engineer, and a banker walk into a pub...the not-so-funny truth about innovation in global health*'. A summary was published on the Academy's website.
- **Encouraging international exchanges.** The Daniel Turnberg UK/Middle East Travel Fellowship Scheme continued to flourish, with an expanding consortium of donors now supporting the scheme. During 2014-5, 21 grants (totalling £83,400) were made to early career biomedical researchers, giving them the opportunity for one month exchanges between institutions in the UK and the Middle East. For the first time in 2014-5, three fellowships were offered to support three month visits.
- **Building relationships with international networks and global Academies.** We continued to play a leadership role in both FEAM and our international network, the InterAcademy Medical Panel (IAMP). The Foreign Secretary represents the Academy on the FEAM Council and is Associate Treasurer, and sits on the Executive Committee of IAMP. We also continued to improve our bilateral relationships, particularly with the US Institute of Medicine, with whom we signed a Memorandum of Understanding, the Leopoldina in Germany and The Academy of Sciences of South Africa.

Future plans

- **Developing our global health programme** by launching a working group project and hosting meetings on key global health topics, for instance on point of care diagnostics and multiple morbidities. Professor Vikram Patel FMedSci will deliver our **2015 International Health Lecture** in October 2015.
- Continuing to **engage with European medical science policy**, particularly to influence European legislation on data protection and discussions about the delivery and use of science advice in Europe.
- **Widening our Newton Fund programme**, by developing partnerships to award fellowships to applicants from other Newton Fund countries. We will award our first Newton International Fellowships and second round of Newton Advanced Fellowships.
- Continuing to work with **networks such as FEAM, the IAMP and the UK Government's Global Science and Innovation Forum** to extend the reach of the Academy's policy influence and impact.
- Developing our relationships with international Academies and global health stakeholders in the UK and overseas.
- Reviewing the **Daniel Turnberg UK/Middle East Travel Fellowships scheme** to ensure it continues to meet researchers' needs.

Encouraging dialogue about medical sciences

Strategic aims

As a National Academy we have a responsibility to communicate the science that we represent to all sectors of society, to show that science is central to modern culture and the hopes and concerns of the society we live in. We aim to ensure that our policy advice is shaped by the views of wider society, and we provide platforms for our Fellows to share their knowledge and expertise with the public. The Academy is a highly valued source of comment on medical science in the media and we continue to increase the Academy's profile through traditional broadcast and print media. We embrace social media and are responsive to changes in online communication to increase public access to our outputs.

Significant activities

- **Building our online community.** We have continued to invest in our website to ensure it remains a modern and accessible 'shop window' for the Academy. In 2014-5 visits have increased by 40% and our new Fellows Directory now receives more than double the number of visitors it had previously. Our social media activities have continued to increase and we have doubled our Twitter followers for the second year running. We have continued our programme of successful Twitter chats, which now occur monthly under the banner of #MedSciLife.
- **Remaining a trusted voice in the media.** Working with journalists, we have ensured Academy views were included in media coverage of topics including the Scottish Referendum, the potential takeover of Astra Zeneca by Pfizer, and the ongoing debate over the prescription of statins. We continued to work with our partner National Academies to highlight in the media the importance of a stable investment framework for research and innovation. Our media liaison has led to coverage in a variety of outlets including the Times, BBC online, the Today programme and Times Higher Education magazine.
- **Fostering a community of researchers skilled at communicating.** Our programme of communications training has equipped young researchers with the skills to communicate their work to a wider audience. Attendees at the 2015 Spring Meeting for Clinician Scientists in Training, and the Winter Meeting 2014, were trained to communicate their work to a wider audience and given the chance to cut their teeth on their first podcast or filmed interview. In April 2014, we held a dedicated communication skills workshop for early career researchers, "*Twitter, TV and beyond*".
- **Addressing the lack of women experts on TV.** We ran three further sessions of our bespoke media training course geared specifically at women Fellows and Academy grant awardees. The course has enabled participants to play their part in increasing the number of women experts in the media, with participants going on to give interviews on the Today programme, 5Live and Women's Hour.
- **Engaging beyond the lecture theatre.** Our programme of public events continued to show how medical science is central to the health, culture and economy of society. In September 2014 Professor Theresa Marteau FMedSci and Professor Tilli Tansey OBE FMedSci joined our first all-female event panel to share their views on public

health at a cinema screening event in Birmingham. In November Professor Sanjeev Krishna FMedSci explored how technology is impacting healthcare at *'The Apothecary: Is the future of medicine calling?'*, which took place in a London workshop space for young technologists and designers.

- **Enabling public input to medical science policy.** In May 2014 the Academy received a People Award from the Wellcome Trust to develop a series of events and workshops to feed public views into the Academy's working group project, *'Health of the public in 2040'*. The outputs from the workshops have already influenced the stimulus material used in an external call for input, and further workshops will ensure public views shape the group's final recommendations in 2016.

Future plans

- **Inspiring others with medical research.** We will support a culture in which scientists are encouraged to communicate their work. We will provide opportunities for the early career researchers with whom we interact to increase their communication skills and to engage the public with their work.
- **Building our press and media capacity.** We will recruit a Senior Press Officer to expand our programme of media training for women and to secure more opportunities for the Academy's voice to be heard in media debates.
- **Involving the views of the public to shape our advice.** We will seek funding and develop partnerships to deliver a major programme of public dialogue to explore a new social contract for medical innovation. We will continue our programme of public engagement using archive public health films to stimulate discussions that will feed public views into our policy project *'Health of the Public 2040'*.
- **Interacting in accessible and innovative ways.** We will continue to develop our website and our social media presence to increase the accessibility of the Academy and our Fellowship for all audiences. We will undertake a major review of the Academy's visual brand and how it is applied across all print and online media, and explore ways to translate our projects into formats easily shared via social media such as infographics, videos and podcasts.
- **Sharing science.** We will expand opportunities for Fellows to share their passion for medical science through events at 41 Portland Place and at various science, art, music and literature festivals.

Governance

Structure, governance and management

The Academy of Medical Sciences is a registered charity and company limited by guarantee. The company was incorporated on 2 March 1998. The Academy is governed by its Memorandum and Articles of Association. The Council members, who are the Trustees of the Academy, are directors under company law.

Fellowship

The Academy is one of the five National Academies of the UK, alongside the Royal Society, the Royal Academy of Engineering, the British Academy and the Royal Society of Edinburgh. The Academy elects Fellows on the basis of sustained and outstanding contributions to the breadth of medical research, including biomedical, clinical and population sciences, as well as veterinary medicine, dentistry, nursing, medical law, health economics and bioethics. Fellows of the Academy are elected for life and designate themselves with the suffix 'FMedSci'. 44 new Fellows were elected in 2014-5 from a pool of over 350 candidates through a rigorous process of peer review, scrutiny from seven Sectional Committees and final election by Council in April. New Fellows are admitted to the Academy at a ceremony in July.

Organisation

The Academy is governed by a Council of 24 Fellows, which meets five times per year. Members of Council are elected from the Fellowship, with nominees confirmed by a ballot of the Fellowship. Council may, from time to time, co-opt additional Fellows to provide a balance of expertise. Fellows elected to Council are amongst the UK's leading medical scientists and hold senior positions in medical schools, universities, research institutes, industry and the civil service; they are well qualified to provide the Academy with the necessary guidance and leadership to achieve its objectives. New Council members are provided with information relating to their responsibilities as trustees of the charity and are inducted at a dedicated session following the February Council meeting. Fellows elected to Council hold office for three years before retiring at the Annual General Meeting in December.

The Council includes six Honorary Officers: President, Vice-President (Clinical), Vice-President (Non-clinical), Treasurer, Registrar and Foreign Secretary. The Honorary Officers are elected by Council from nominations received from the Fellowship; they hold office for four years, with one (or two) of the six retiring each year.

The Honorary Officers and Council set the strategic direction of the Academy and oversee the work of the secretariat. Academy activities are selected by Council for the contribution they make towards the Academy's strategic goals, and are informed by the independent opinion, experience and expertise of the Fellowship. Council is advised by several committees, including the group of Honorary Officers, who meet seven times per year. The Finance Committee meets three times a year and reports directly to Council; it reviews the audited financial statements and recommends their approval to Council, reviews the management of the Academy's assets, reviews reports from the external auditors and oversees the implementation of any recommendations thereafter.

Volunteers

The Academy is grateful for the valuable contribution to its work that is made voluntarily by both Fellows and non-Fellows. Fellows and external advisers serve the Academy without compensation in a range of activities: as Officers, Council members and committee members, as members of working groups, as speakers and participants in symposia, as providers of evidence for Academy studies, as peer reviewers for grant applications, as mentors to medical trainees, and in many more ways. Fellows also act as Academy representatives on many external bodies.

Risk assessment

The Finance Committee advises Council and the Honorary Officers on the risks to which the Academy is exposed. It does this by regularly reviewing all elements of Academy business to ensure that potential risks are identified and processes implemented to mitigate those risks. The key strategic risks of the Academy are the risk to its reputation and its need for continued external income.

Management and staffing

The Executive Director is responsible for the day-to-day management of the Academy and its activities, and is supported by a Senior Management Team of four Directors responsible for Finance and Resource, Grants and Careers, Medical Science Policy and Communications. The Executive Director leads a permanent staff of 27.

Public benefit

Council has discussed the implications of the provisions of the Charities Act 2011, which states that all charities must demonstrate that they are established for public benefit and have had due regard to the public benefit guidance issued by the Charity Commission. Council is confident that activities planned under the six priority programmes fulfil the Academy's aims to ensure that advances in medical science are translated into healthcare benefits to the public.

Grants

The Academy's targeted research funding schemes are offered to a range of aspiring medical researchers. Each of the schemes operate specific eligibility and funding criteria, but all schemes are aimed at supporting those who demonstrate significant potential. The schemes are widely publicised and a robust selection process is operated; final appointments are made by an expert panel, which may draw on peer reviews by Academy Fellows. Grant holders are required to submit progress reports, which are reviewed by experts in the field.

Financial review

The Consolidated Statement of Financial Activities (SOFA) and Balance Sheet, together with the Notes to the Accounts set out on pages 27-41, show the overall financial performance of the Academy group and provide an analysis of the incoming resources and how they were applied in the performance of the Academy's objectives.

Results for the year

2014/15 was another successful year for the Academy group, with total incoming resources increasing significantly, from £4.36 million to £5.80 million. Much of the increase was due to a new fundraising initiative, and the expansion of our grants portfolio to include a new international scheme supported by the UK government's Newton Fund. Each year the majority of the Academy's income is received in support of specific programmes or activities and so we monitor income that has no such restriction closely. In 2014/15, despite a decrease in the unrestricted income received into the General Fund, we were able to sustain a small surplus on the Fund, thereby consolidating the positive performance from 2013/14. This is an encouraging result in a year where we actively strengthened the operational platform and staff support, and represents a further step in our strategic aim of improving the financial sustainability of the Academy for the longer term.

Funding sources

Total incoming resources for the year were £5,799,261, an increase of 33% on 2013/14. *Voluntary income* was improved in the year to £1,410,472, largely as a result of the Academy's new fundraising campaign set out in the Case for Support launched in Spring 2014. It set a target of raising £5 million of new income to transform the Academy's capacity and facilitate a step change in activities. By the end of March 2015 just under £900,000 had been pledged with £363,066 being received into a newly designated Development Fund to enable the Academy to initiate or scope new activities without relying on external funding. Monies received from the campaign for specific new activities are shown under *grants and donations for specific purposes* and this includes over £100,000 received to support our major policy projects on Health of the Public 2040 and Research Reproducibility. Total *Grants and donations* were £3.52 million, an increase of £1.15 million from the previous year. The new funding received from the Newton Fund made a particular impact, with a total of £437,500 being received. There was also an increase in the income received for our work on *Nurturing the next generation* as a result of funding for the second round of awards under the INSPIRE scheme (£326,421) and a full year of grants for the Clinician Scientist Fellowships under the 2013/14 cohort (£590,922).

Expenditure

Total expenditure was £5,560,909 compared to £4,462,289 in the previous year. We were particularly pleased to be able to increase the spending under our international strategic objective as a result of the new Newton Fund programme. Expenditure rose from £144,925 to £651,025 including grant funding and additional staff support. Our work on *Nurturing the next generation* also benefited from an increase in expenditure with the INSPIRE scheme awards and grants under the Clinician Scientist Fellowships.

We actively invested in the fundraising and operational support to the Academy during the year and although this had an immediate impact in increasing voluntary income, it also meant that

fundraising and support costs increased. However, we are now better placed to deliver the ambitious programme of activities planned as part of the grant from the Department of Business Innovation and Skills that commences in April 2015.

During the year the Finance Committee and Council approved the refurbishment of 8 Weymouth Mews to provide additional office space for external letting in order to enhance unrestricted income. The works were financed by a bank loan details of which are shown at Note 11 to the accounts. Building costs and associated professional fees of £156,361 have been capitalised and shown under *additions to leasehold improvements*, with any repair works being included under *costs of generating funds*. The refurbishment was completed on 30 April.

Cash and investment management

Investments were valued at £2,145,608 at 31 March 2015 with a £180,445 increase in market value. The investments are held in the Sarasin & Partners Alpha Common Investment Fund (CIF) for Endowments and Alpha CIF for Income and Reserves, in proportions agreed with the investment managers to fulfil the investment objectives of the four individual portfolios. The Finance Committee confirmed that those objectives were being achieved at their meeting in February 2015.

The terms of the Academy's grant schemes require that substantial cash deposits are received from funders in advance of award rounds and at 31 March 2015 cash on deposit was £3.87 million, £1.19 million of which was held in advance for grants. The cash management policy, which is reviewed regularly by the Finance Committee, recommends the diversification of deposits with the use of pooled cash deposit funds and the placing of cash on term deposit with selected banks to a maximum limit for each banking group.

Reserves

The Academy's reserves at 31 March 2015 were £9,859,566 million, an increase of £418,797 from 31 March 2014. The reserves were made up as follows:

	£
Permanent Endowment	1,615,592
Restricted Funds	4,745,875
Unrestricted Funds	
Designated Funds	2,968,407
General Fund	529,692
Total Funds at 31 March 2015	9,859,566

The Finance Committee reviews the level of reserves regularly to ensure that they are appropriate for the purposes for which they are retained. The purposes of the permanent endowment and restricted funds are outlined in Note 13 to the Accounts.

The General Fund is held to protect the Academy's core activities against potential shortfalls in funding. The Finance Committee recognised the risk to the General Fund of increased costs associated with the new headquarters at 41 Portland Place and provided against specific risks in three designated funds.

The first is a fund to cover the risk of the trading subsidiary not being able to repay its start up loan, currently £100,000. The loan facility allows for a maximum amount of £200,000 and a balance of £200,422 was retained at 31 March 2015 in the Business Designated Fund. The second fund, the Building Repair Fund, was established by the Finance Committee in February 2012 to provide for the long term repair and renewal costs of the building up until the termination of the lease. The balance at 31 March 2015 was £268,693 after expenditure of £34,231 and a transfer of £80,000 from the General Fund. It is planned that payments will continue to be made regularly from the core budget into the Building Repair Fund. The third designated fund is an asset fund of £2.14 million against which depreciation of the leasehold at 41 Portland Place / 8 Weymouth Mews is charged over the remaining term of the lease.

The Finance Committee designated a new fund during the year; the Development Fund, to be used for donations received under the Case for Support 2014. Donations totalling £363,066 were received in the year and will be used under the broad objectives of policy and career support as outlined in the fundraising literature.

Reserves policy

The Finance Committee regularly reviews the level of reserves retained in the General Fund with reference to the income sources and assets of the Academy. At its meeting in November 2014 the Finance Committee approved the increase of the target level of free reserves to a range of £450,000 to £500,000. With an increased staff establishment and operational platform, this level of reserve would allow the Academy to restructure activities to a level that would be appropriate for a reduced amount of General Fund income in the event of a significant shortfall in core funding. The level of free reserves (General Fund less the net book value of fixed assets in that Fund) at 31 March 2015 was £481,367 and within the target range.

Statement of Trustees' responsibilities

The trustees (Council) who are also directors of the Academy of Medical Sciences for the purposes of company law, are responsible for preparing the Council report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company and charity law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent charity and of the outgoing resources and application of resources, including its income and expenditure, of the group for the year. In preparing those financial statements the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping adequate and sufficient accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the group and parent charity and enable them to ensure that the financial statements comply with the Charities Act 2011 and regulations made thereunder and with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements and other information included in annual reports may differ from legislation in other jurisdictions.

Disclosure of information to the auditors

The trustees who held office at the date of approval of this report confirm that, so far as they are each aware, there is no relevant audit information of which the Academy's auditors are unaware; and each trustee has taken all the steps that he / she ought to have taken as a trustee to make himself / herself aware of any relevant audit information and to establish that the Academy's auditors are aware of that information.


Small company rules

These accounts have been prepared in accordance with the special provisions of part 15 of the Companies Act 2006, relating to small companies.

Approved by the Council on 25 June 2015 and signed on its behalf by:

Professor Sir John Tooke PMedSci

President



Independent auditor's report to the trustees and members of the Academy of Medical Sciences

We have audited the financial statements of the Academy of Medical Sciences for the year ended 31 March 2015 which comprise the Consolidated Statement of Financial Activities, the Group and Charity Balance Sheets, and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charity's trustees and members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and the Charities Act 2011. Our audit work has been undertaken so that we might state to the charity's trustees and members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees and members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the Academy of Medical Sciences for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Financial Reporting Council's (FRC's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the FRC's website at www.frc.org.uk/auditscopeukprivate.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the group's and charity's affairs as at 31 March 2015 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Act 2011 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime, take advantage of the small companies exemption in preparing the Statement of Trustees' Responsibilities or the exemption from the requirements to prepare a strategic report.

BDO LLP

Don Bawtree, Senior Statutory Auditor
for and on behalf of BDO LLP, Statutory Auditor
London
United Kingdom

Date: 30 June 2015

BDO LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Consolidated statement of financial activities for the year ended 31 March 2015

(Incorporating an income and expenditure account)

	Note	General Fund £	Designated Funds £	Restricted Funds £	Permanent endowment Funds £	Total 2015 £	Restated Total 2014 £
Incoming resources							
<i>Incoming resources from generated funds</i>							
Voluntary income		770,992	448,066	97,100	94,314	1,410,472	982,213
Activities for generating funds		773,787	-	-	-	773,787	932,876
Investment income		29,465	-	32,882	36,142	98,489	78,159
<i>Incoming resources from charitable activities</i>							
Grants and donations		59,000	-	3,457,513	-	3,516,513	2,366,194
Total incoming resources	3	1,633,244	448,066	3,587,495	130,456	5,799,261	4,359,442
Resources expended							
<i>Costs of generating funds</i>							
	4a	726,558	28,735	15,983	9,918	781,194	730,218
<i>Charitable activities</i>							
Promoting excellence		239,952	10,082	29,206	-	279,241	311,158
Nurturing the next generation		90,876	40,395	3,000,117	-	3,131,388	2,570,847
Influencing policy		199,316	17,015	158,683	-	375,013	288,103
Seizing international opportunities		77,621	10,311	522,496	40,597	651,025	144,925
Linking academia, industry & NHS		79,216	5,629	63,126	-	147,971	166,375
Encouraging dialogue		102,453	3,849	27,634	-	133,936	124,618
		789,434	87,281	3,801,262	40,597	4,718,574	3,606,026
<i>Governance costs</i>	4c	57,896	1,098	2,147	-	61,141	64,417
<i>Other resources expended</i>		-	-	-	-	-	61,628
Total resources expended	4	1,573,888	117,114	3,819,392	50,515	5,560,909	4,462,289
Net (outgoing) / incoming resources before transfers		59,356	330,952	(231,897)	79,941	238,352	(102,847)
Gross transfers between Funds	14	(48,423)	80,000	(31,577)	-	-	-
Gains on investment assets	9	9,397	-	41,034	130,014	180,445	22,585
Net movement in funds		20,330	410,952	(222,440)	209,955	418,797	(80,262)
Funds 1 April 2014		509,362	2,557,455	4,968,315	1,405,637	9,440,769	9,521,031
Funds 31 March 2015	13	529,692	2,968,407	4,745,875	1,615,592	9,859,566	9,440,769

All amounts relate to continuing operations.

There are no recognised gains or losses other than those in the statement of financial activities.

The notes on pages 29 - 41 form part of these financial statements.

Balance sheets as at 31 March 2015

	Note	Group 2015 £	Charity 2015 £	Group 2014 £	Charity 2014 £
Tangible fixed assets	8	5,782,860	5,782,860	5,790,932	5,790,932
Investments	9	2,145,608	2,146,608	2,020,265	2,021,265
Current assets					
Debtors	10	322,163	377,644	199,226	377,305
Stock		3,737	-	4,094	-
Cash on deposit		3,867,074	3,867,074	2,095,023	1,995,023
Cash at bank and in hand		217,576	57,598	210,365	42,237
		4,410,550	4,302,316	2,508,708	2,414,565
Current liabilities					
Creditors: amounts falling due within one year	11	(2,255,922)	(2,148,688)	(879,136)	(785,993)
Net current assets		2,154,628	2,153,628	1,629,572	1,628,572
Creditors: amounts falling due After one year	11	(223,530)	(223,530)	-	-
Net assets	15	9,859,566	9,859,566	9,440,769	9,440,769
Represented by:					
Permanent endowment funds		1,615,592	1,615,592	1,405,637	1,405,637
Restricted funds		4,745,875	4,745,875	4,968,315	4,968,315
Unrestricted funds:					
General fund		529,692	529,692	509,362	509,362
Designated fund		2,968,407	2,968,407	2,557,455	2,557,455
Total funds	13	9,859,566	9,859,566	9,440,769	9,440,769

These accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the Council and authorised for issue on 25 June 2015, and signed on its behalf by:



President

Professor Sir John Tooke PMedSci



Treasurer

Professor Anne Dell CBE FRS FMedSci

The notes on pages 29 - 41 form part of these financial statements.
Company Number 3520281

Notes to the financial statements for the year ended 31 March 2015

1 Accounting policies

The principal accounting policies applied in the preparation of the financial statements are described below.

a. Basis of preparation of accounts

The financial statements have been prepared under the historical cost convention and comply with the Companies Act 2006. They have been prepared in accordance with applicable accounting standards and the requirements of the Statement of Recommended Practice on Accounting and Reporting by Charities (SORP 2005).

The financial statements include transactions, assets and liabilities of Academy of Medical Sciences Trading Limited, a wholly owned subsidiary company of the Academy of Medical Sciences on a line by line basis. Transactions and balances between the Academy and its subsidiary have been eliminated from the consolidated financial statements. Balances between the two entities are disclosed in the notes of the Academy's balance sheet. The subsidiary's accounts are produced separately as required by the Companies Act 2006 and are summarised at Note 2. No separate Statement of Financial Activities has been presented for the charity alone, as permitted by section 408 of the Companies Act 2006 and paragraph 397 of the SORP.

b. Incoming resources

Voluntary income received by way of donations and gifts is included in full in the statement of financial activities when receivable.

Activities for generating funds – trading income is recognised when services are delivered and is net of VAT.

Investment income is recognised on a receivable basis.

Grants are credited to the statement of financial activities when received or receivable, whichever is earlier. Where entitlement to grants receivable is dependent upon fulfilment of conditions within the Academy's control, the incoming resources are recognised when there is sufficient evidence that conditions will be met. Where there is uncertainty as to whether the Academy can meet such conditions, the incoming resource is deferred. Where amounts are received which relate specifically for use in a future period, they are deferred and recognised in the accounting period to which they relate, where entitlement arises.

Donated services are recognised when the benefit to the charity is reasonably quantifiable and measurable. The value placed on these services is the estimated value to the charity of the service received. The value is included in incoming resources and a corresponding amount is shown as expenditure under the relevant charitable activity.

c. Resources expended

All expenditure is accounted for on an accruals basis and has been listed under headings that aggregate all the costs related to that activity. Where costs cannot be directly attributed (support costs) they have been allocated to activities on the basis of the average amount of staff time spent on each activity, except where the terms of restricted funding specifies a particular overhead recovery.

Governance costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements. The costs of Council meetings and the Annual General Meeting, together with related Fellows' travel costs, are included.

Costs of generating funds include fundraising costs expended in seeking new sources of funding for the Academy; the costs of conferencing and office rentals in the trading company; and expenditure on property to be used to generate income.

Other resources expended relate to costs associated with non routine building improvements and property management advice. The comparative figures for 2013/14 have been restated to reallocate regular repairs to support costs.

Grants payable – Clinician Scientist Fellowships, Starter Grants for Clinical Lecturers and Newton Fellowships are charged in the year when the conditions for each award are fulfilled. Grants awarded under the Daniel Turnberg Memorial Fund are treated as payable only when funding is in place.

d. Tangible fixed assets

Tangible fixed assets are included at cost except for the leasehold premises, which are held at market value, and antiques, which are shown at their insurance value. Because of the long term nature of their use, the Academy does not consider it appropriate to charge annual depreciation.

Fixed assets costing more than £500 are capitalised and included on the balance sheet. Depreciation is provided on a straight-line basis on tangible fixed assets so as to write them off over their anticipated useful economic lives at the following annual rates:

Furniture, fixtures and office equipment	10%
Computer and audio visual equipment	25%
Leasehold premises and refurbishment	in equal instalments over the remaining term of the original lease

e. Operating leases

The charity classifies the lease of photocopying equipment as an operating lease. Rental charges are charged on a straight line basis over the term of the lease.

f. Investments

Investments are included at market value at the year end. However, the investment in the trading company in the charity only balance sheet is at cost. The Statement of Financial Activities includes the net gains and losses arising on revaluations and disposals throughout the year.

g. Funds

Unrestricted funds comprise a General Fund, held for the general objects of the Academy's work, and several Designated Funds which have been earmarked by the Council for specific purposes; a Business Fund to support the trading subsidiary, an Asset Fund for the leasehold premises at 41 Portland Place, a Building Repair Fund to provide for the future maintenance of the property and a Development Fund to hold significant unrestricted donations.

Restricted funds are funds used for specific purposes as required by the donor. Permanent endowment funds are restricted funds that the donor has stated are to be held as capital.

h. Pension policy

The Academy operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Academy in an independently administered scheme. The pension cost charge represents contributions payable under the scheme by the charity to the fund. The charity has no liability under the scheme other than for the payment of those contributions.

i. VAT

The Academy is registered for VAT and, as a result of a significant part of its activities being exempt or outside the scope of VAT, is not able to recover all the purchase VAT relating to those activities. An amount of irrecoverable VAT of £90,821 (2014: £85,655) has been included in resources expended and allocated to the relevant cost headings on the basis described at (c) above.

2 Results of the subsidiary company

The charity has one wholly owned subsidiary company, Academy of Medical Sciences Trading Limited, which was incorporated in England and Wales on 25 February 2010 with registered number 07170258. The Academy invested £1,000 in the £1 ordinary shares of the company on 1 April 2010 and made an initial loan of £100,000 secured under a debenture so that the company could cover the set up costs of the new conferencing business at 41 Portland Place. A summary of the results for the year and the balance sheet at 31 March 2015 are shown below.

Profit & loss account

	2015 £	2014 £
Turnover	860,769	989,186
Costs of sales	(591,534)	(606,674)
Gross profit	269,235	382,512
Administrative expenses	(214,470)	(281,739)
Operating profit for the year	54,765	100,773
Interest receivable	232	771
Interest payable	(3,500)	(3,500)
Donation to the charity	(51,497)	(98,044)
Profit for the year	-	-

Balance sheet

Current assets	289,321	377,938
Current liabilities	(188,321)	(276,938)
Net current assets	101,000	101,000
Loan from the charity	(100,000)	(100,000)
Net assets / (liabilities)	1,000	1,000

Share capital and reserves

Share capital	1,000	1,000
Profit & loss account	-	-
Shareholders' funds	1,000	1,000

On consolidation these results have been adjusted to eliminate income from meeting room hire to the Academy and rent payable to the Academy under a head lease. The balance is included as income £773,787 and expenditure £601,061 at Notes 3a and 4a: Conferencing and office rentals.

The parent charity's income and the results for the year are disclosed as follows:

	2015 £	2014 £
Income	5,186,432	3,666,741
Net movement in funds for the year	418,797	(80,262)

3 Incoming resources

a. Incoming resources from generated funds

	General Fund 2015	Other Funds 2015	Total Funds 2015	Total Funds 2014
	£	£	£	£
<i>Voluntary income</i>				
Fellows' subscriptions and contributions	289,968	-	289,968	246,510
Donations – capital appeal	-	-	-	41,858
Donations – development fund	-	363,066	363,065	-
Donations – Department of Health	464,000	-	464,000	457,000
Donations – core funds	17,025	-	17,025	26,072
Donations – Daniel Turnberg Memorial Fund	-	94,313	94,314	99,983
Donated staff	-	67,100	67,100	80,790
Donated services	-	30,000	30,000	30,000
Donated assets	-	85,000	85,000	-
	770,993	639,479	1,410,472	982,213
<i>Activities for generating funds</i>				
Conferencing and office rentals	773,787	-	773,787	929,959
Other rental income	-	-	-	2,917
	773,787	-	773,787	932,876
<i>Investment income</i>				
Income on investments	7,482	63,961	71,443	43,826
Short term deposit interest	21,816	5,064	26,880	34,068
Bank deposit interest	166	-	166	265
	29,464	69,025	98,489	78,159
Total incoming resources from generated funds	1,574,244	708,504	2,282,748	1,993,248

b. Incoming resources from charitable activities

	General Fund 2015	Other Funds 2015	Total Funds 2015	Total Funds 2014
	£	£	£	£
<i>Grants and donations for specific purposes</i>				
Nurturing the next generation - careers	-	859,928	859,928	559,080
Nurturing the next generation - fellowships	-	1,949,676	1,949,676	1,650,034
Influencing policy	-	109,500	109,500	-
Linking academia, industry & NHS	59,000	25,000	84,000	97,500
Seizing international opportunities	-	493,300	493,300	59,580
Encouraging dialogue	-	20,109	20,109	-
Total incoming resources from charitable activities	59,000	3,457,513	3,516,513	2,366,194
Total incoming resources	1,633,244	4,166,017	5,799,261	4,359,442

4 Resources expended

a. Analysis of total resources expended

	Direct Costs £	Grant funding £	Support costs £	Total 2015 £	Restated Total 2014 £
<i>Costs of generating funds</i>					
Fundraising costs	99,616	-	57,997	157,613	91,581
Property management	22,520	-	-	22,520	-
Conferencing and office rentals	601,061	-	-	601,061	638,637
	<u>723,197</u>	<u>-</u>	<u>57,997</u>	<u>781,194</u>	<u>730,218</u>
<i>Charitable activities</i>					
Promoting excellence	185,197	-	94,044	279,241	311,158
Nurturing the next generation	851,946	1,902,651	376,791	3,131,388	2,570,847
Influencing policy	216,305	-	158,708	375,013	288,103
Seizing international opportunities	120,179	434,667	96,179	651,025	144,925
Linking academia, industry & NHS	95,468	-	52,503	147,971	166,375
Encouraging dialogue	98,033	-	35,903	133,936	124,618
	<u>1,567,128</u>	<u>2,337,318</u>	<u>814,128</u>	<u>4,718,574</u>	<u>3,606,026</u>
<i>Governance</i>	50,900	-	10,241	61,141	64,417
<i>Other resources expended</i>	-	-	-	-	61,628
Total resources expended	<u>2,341,225</u>	<u>2,337,318</u>	<u>882,366</u>	<u>5,560,909</u>	<u>4,462,289</u>

The figures for 2013/14 have been restated to reallocate regular repairs of £23,706 from other resources expended to support costs.

b. Analysis of support costs

	Cost of premises £	Office & IT costs £	Staff & related costs £	Total 2015 £	Restated Total 2014 £
<i>Costs of generating funds</i>	28,271	9,644	20,082	57,997	30,295
<i>Charitable activities</i>					
Promoting excellence	45,842	15,638	32,564	94,044	122,540
Nurturing the next generation	183,668	62,655	130,468	376,791	443,009
Influencing policy	77,363	26,391	54,954	158,708	132,976
Seizing international opportunities	46,883	15,993	33,303	96,179	18,563
Linking academia, industry & NHS	25,593	8,730	18,180	52,503	59,403
Encouraging dialogue	17,501	5,970	12,432	35,903	46,334
<i>Governance</i>	4,992	1,703	3,546	10,241	12,475
Total support costs	<u>430,113</u>	<u>146,724</u>	<u>305,529</u>	<u>882,366</u>	<u>865,595</u>

Support costs, which include the depreciation charge for the year, are allocated on the basis of average staff time except where the terms of restricted funding specify a particular overhead recovery.

c. Analysis of governance costs

	2015 £	2014 £
Audit fees - charity	12,480	12,120
Audit fees – trading subsidiary	1,650	1,600
Costs of AGM and Council meetings	20,219	18,895
Staff and related costs	16,550	13,768
Strategy planning days	-	5,559
Allocated support costs	<u>10,242</u>	<u>12,475</u>
Total governance costs	<u>61,141</u>	<u>64,417</u>

The auditors also provided professional advice in the year of £400 (2014: £5,850) which is included in office costs.

5 Trustee and employee information**d. Trustee information**

None of the Council (trustees) received or waived emoluments in the current or preceding year.

During the year 22 Council members (2014: 21) received reimbursed travel expenses of £14,592 (2014: £13,362).

e. Employee information

	2015 £	2014 £
Salaries	968,612	777,195
Employer's national insurance	98,988	80,263
Employer's pension contributions	54,731	53,883
Donated staff services	<u>67,100</u>	<u>80,790</u>
	<u>1,189,431</u>	<u>992,131</u>

The full-time average equivalent for salaried staff during the year was 23.94 (2014: 20.2).

The number of employees whose emoluments as defined for taxation purposes amounted to over £60,000 in the year was as follows:

	2015	2014
£60,001 - £70,000	1	-
£70,001 - £80,000	<u>1</u>	<u>1</u>

Pension contributions paid by the Academy relating to the higher paid employees as defined above amounted to £10,800 (2014: £5,850)

6 Net (outgoing)/incoming resources after charging:

	2015 £	2014 £
Audit fees - charity	12,480	12,120
Audit fees – trading subsidiary	1,650	1,600
Investment management fees	15,168	10,563
Depreciation of tangible fixed assets	276,261	293,465
Operating lease charges	<u>3,736</u>	<u>3,736</u>

7 Grants payable

The Academy administers four grant schemes: the Clinician Scientist Fellowship Scheme (CSFS) funded by the Health Foundation; the Starter Grants for Clinical Lecturer Scheme (CLS) funded by the Wellcome Trust, the British Heart Foundation, Arthritis Research UK, the Medical Research Council, the Royal College of Physicians and Prostate Cancer UK; the Newton Fellowships (NFS) funded by the Newton Fund (Department for Business Innovation & Skills) and the Daniel Turnberg UK/Middle East Travel Fellowship Scheme (DTMF). Details of the Schemes are as follows:

	CSFS £	CLS £	NFS £	DTMF £	Total 2015 £
Grants outstanding 1 April	36,958	-	-	-	36,958
Grants awarded in the year	543,897	1,358,754	352,000	82,667	2,337,318
Grants paid in the year	<u>(457,200)</u>	<u>(1,358,754)</u>	<u>(352,000)</u>	<u>(82,667)</u>	<u>(2,250,621)</u>
Grants outstanding 31 March	<u>123,655</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>123,655</u>
Grants to institutions to nurture the next generation	543,897	1,358,754	-	-	1,902,651
Grants to institutions to seize international opportunities	-	-	352,000	-	352,000
Grants to individuals to seize international opportunities	-	-	-	82,667	82,667
Grants awarded in the year	<u>543,897</u>	<u>1,358,754</u>	<u>352,000</u>	<u>82,667</u>	<u>2,337,318</u>

Grants to the Royal Society under the Newton Fellowships scheme totalled £352,000. Grants to 21 other institutions were paid in the year to a total value of £1,815,954. The principal institutions benefiting from the grants were:

£

King's College, London	345,322
University of Cambridge	283,959
University of Oxford	228,341
Imperial College, London	174,335

8 Tangible fixed assets – Group and Charity

	Leasehold Premises £	Refurbished Property £	Furniture, fixtures & equipment £	Computer equipment £	Total £
Cost					
At 1 April	2,300,000	3,974,596	345,285	208,957	6,828,838
Additions	-	156,361	93,606	18,222	268,189
Disposals	-	-	-	(9,192)	(9,192)
At 31 March	2,300,000	4,130,957	438,891	217,987	7,087,835
Depreciation					
At 1 April	290,091	501,300	71,911	174,604	1,037,906
Charge for the year	82,883	143,228	21,075	29,075	276,261
Disposals	-	-	-	(9,192)	(9,192)
At 31 March	372,974	644,528	92,986	194,487	1,304,975
Net book value					
31 March 2015	1,927,026	3,486,429	345,905	23,500	5,782,860
31 March 2014	2,009,909	3,473,296	273,374	34,353	5,790,932

Leasehold premises represents the value of the leasehold property at 41 Portland Place/8 Weymouth Mews as transferred to the Academy from the Novartis Foundation on 31 July 2008.

Refurbished property represents the costs of construction and associated professional fees incurred in the refurbishment of 41 Portland Place between 2009 and 2011. The additions during the year are for the refurbishment work on 8 Weymouth Mews.

On 22 April 2014 the Academy completed on a new over-riding lease with the immediate landlords QAS Nominees Ltd that extends the current lease term on 41 Portland Place and 8 Weymouth Mews from 2038 to 2137. The rent payable from 6 July 2038 will be at full market rate rather than at the peppercorn rent paid currently. This means that the capital value will expire in July 2038 and depreciation will therefore continue to be calculated on the original lease term.

Included in furniture, fixtures and equipment are antiques that are held as artefacts for the long term and depreciation, which would be immaterial, has not been charged on them. With regular maintenance their initial carrying value should be maintained and no impairment review is considered necessary.

9 Investments - Group

	2015 £	2014 £
At 1 April	2,000,050	1,121,034
Additions	60,690	866,994
Disposals	(141,243)	(10,563)
Net gain in market value	<u>180,445</u>	<u>22,585</u>
	2,099,942	2,000,050
Cash held for investment	<u>45,666</u>	<u>20,215</u>
Market Value at 31 March 2015	<u><u>2,145,608</u></u>	<u><u>2,020,265</u></u>
Cost at 31 March 2015	<u><u>1,778,489</u></u>	<u><u>1,799,152</u></u>

Investments to the value of £308,039 representing the Jean Shanks Memorial and the Sackler endowed funds are held in the Sarasin & Partners Alpha Common Investment Fund for Endowments. Investments to the value of £1,163,624 representing the Daniel Turnberg Memorial Fund are split between the Sarasin & Partners Alpha Common Investment Fund for Endowments and their Alpha Common Investment Fund for Income and Reserves. Additional investments to the value of £673,945 comprising balances held in the General Fund and Restricted Funds that are identified as suitable for retention in the medium term are split across the two Sarasin Funds as previously mentioned.

Investments of £2,146,608 shown in the Charity only balance sheet include an investment in the Academy of Medical Sciences Trading Limited share capital of £1,000 which is valued at cost.

10 Debtors

	Group 2015 £	Charity 2015 £	Group 2014 £	Charity 2014 £
Amounts falling due within one year:				
Trade debtors	166,863	86,565	82,423	38,649
Prepayments	76,285	76,285	59,651	59,651
Accrued income	10,327	10,327	3,932	3,932
VAT recoverable	15,076	22,091	3,670	-
Other debtors	53,612	18,612	49,550	14,550
Amount due from subsidiary	-	63,764	-	160,523
Amount falling due after more than one year:				
Loan to subsidiary	-	100,000	-	100,000
	<u>322,163</u>	<u>377,644</u>	<u>199,226</u>	<u>377,305</u>

11 Creditors

	Group 2015 £	Charity 2015 £	Group 2014 £	Charity 2014 £
Amounts falling due within one year:				
Grants payable	123,655	123,655	36,958	36,958
Trade creditors	580,054	521,096	322,708	227,399
Accruals	45,213	42,097	20,948	18,449
Deferred income	1,461,048	1,415,888	474,923	460,935
PAYE/NIC Liability	24,697	24,697	23,599	23,599
VAT payable	-	-	-	18,653
Bank loan	<u>21,255</u>	<u>21,255</u>	<u>-</u>	<u>-</u>
	<u><u>2,255,922</u></u>	<u><u>2,148,688</u></u>	<u><u>879,136</u></u>	<u><u>785,993</u></u>

Amounts falling due beyond one year:

	Group 2015 £	Charity 2015 £	Group 2014 £	Charity 2014 £
Bank loan				
Due within two to five years	93,311	93,311	-	-
Due after five years	130,219	130,219	-	-
	223,530	223,530	-	-

The Academy has a secured loan of £250k with Lloyds repayable over 10 years. Interest is payable at a fixed rate of 4.31% on £125,000 and at a variable rate of 2.56% above base rate on the remaining £125,000 of capital.

12 Deferred Income

	Group 2015 £	Charity 2015 £	Group 2014 £	Charity 2014 £
Deferred income brought forward	474,923	460,935	526,576	416,335
Less: Amount used in the year	(474,923)	(460,935)	(526,576)	(416,335)
<i>Income accrued within the year:</i>				
Grants from institutions	1,415,888	1,415,888	460,935	460,935
Conferencing deposits	45,160	-	13,988	-
Deferred income carried forward	1,461,048	1,415,888	474,923	460,935

NOTES TO THE FINANCIAL STATEMENTS

13 Movement on group funds	Balance 1 April £	Income £	Expenditure £	Transfers £	Revaluation £	Balance 31 March £
Permanent endowment						
Jean Shanks Memorial Fund	212,280	-	(1,613)	-	20,303	230,970
Sackler Fund	70,763	-	(538)	-	6,768	76,993
Daniel Turnberg Memorial Fund	1,122,594	130,456	(48,364)	-	102,943	1,307,629
Total permanent endowment	1,405,637	130,456	(50,515)	-	130,014	1,615,592
Restricted funds						
Grant schemes	324,011	2,236,788	(2,189,629)	(10,007)	-	361,163
Newton grant scheme	-	437,500	(437,500)	-	-	-
Mentoring & career development	50,326	624,247	(649,805)	(8,642)	-	16,126
Project & meeting contributions	14,937	231,423	(215,906)	(4,436)	-	26,018
Medical Research Society	896,024	56,877	(138,985)	(8,492)	41,034	846,458
Capital Appeal	56,123	660	(2,622)	-	-	54,161
Restricted Asset Fund	3,626,894	-	(184,945)	-	-	3,441,949
Total restricted funds	4,968,315	3,587,495	(3,819,392)	(31,577)	41,034	4,745,875
Unrestricted funds						
General Fund	509,362	1,633,244	(1,573,888)	(48,423)	9,397	529,692
Designated funds						
Business Fund	200,422	-	-	-	-	200,422
Asset Fund	2,134,109	85,000	(82,883)	-	-	2,136,226
Building Repair Fund	222,924	-	(34,231)	80,000	-	268,693
Development Fund	-	363,066	-	-	-	363,066
Total designated funds	2,557,455	448,066	(117,114)	80,000	-	2,968,407
Total unrestricted funds	3,066,817	2,081,310	(1,691,002)	31,577	9,397	3,498,099
Total funds	9,440,769	5,799,261	(5,560,909)	-	180,445	9,859,566

ENDOWMENT FUNDS

The Jean Shanks Memorial Fund

This fund is held in perpetuity to fund an annual Jean Shanks Memorial Lecture. Income arising from the investment of the donation is treated as restricted income.

The Sackler Fund

This fund was donated by The Raymond and Beverly Sackler Foundation to be held in perpetuity to fund an annual lecture. Income arising from the investment of the donation is treated as restricted income.

The Daniel Turnberg Memorial Fund

The Academy holds funds as sole trustee of the Daniel Turnberg Memorial Fund set up to foster academic interchange between medical and bioscience researchers in and between the UK and countries in the Middle East by award of travel grants.

RESTRICTED FUNDS

Grant Schemes

The Academy's four grant schemes are funded by external organisations as detailed in note 7. Balances held at the end of the year include £325,175 remaining from the early cohorts of the Clinician Scientist Fellowship Scheme (CSFS). The Newton Fellowships, funded by the Department for Business Innovation & Skills, are disclosed separately as required by the terms of the grant. During the year £352k of grant funding and £85,500 contribution for the running of the scheme was received and expended.

Mentoring and career development programme

The National Institute for Health Research (NIHR) and the Wellcome Trust fund our mentoring and career development programme with supplementary funding received from the Medical Research Council, NHS Education for Scotland, Queen's University, Belfast and the National Institute for Social Care and Health Research in Wales.

Project/meeting contributions

Specific donations to support meetings and other activities.

Medical Research Society

The Medical Research Society merged with the Academy on 31st October 2011 and the monies transferred on merger have been retained by the Academy to fulfil the charitable objectives of the Society and particularly to support the Annual Spring Meeting for Clinician Scientists in Training.

Capital appeal

The balance remaining from donations received in response to the Academy's fundraising appeal to support the refurbishment of 41 Portland Place. The monies are held to support further capital investment in the building.

Restricted Asset Fund

This fund represents the assets that were funded by the Capital Appeal in 2009-11.

DESIGNATED FUNDS

Designated Business Fund

This fund is being used to support the trading subsidiary during the first years of its operation.

Designated Asset Fund

This fund comprises the value of the leasehold premises, antiques and paintings at 41 Portland Place and 8 Weymouth Mews in July 2008 on merger with the Novartis Foundation, less associated depreciation.

Designated Building Repair Fund

This fund provides for future building repairs and major equipment purchases at 41 Portland Place over the length of the lease.

Designated Development Fund

This fund has been set up from significant unrestricted donations received by the Academy as part of the 2014 Case for Support to be used for policy and career support.

14 Transfer between funds

	General Fund £	Designated Funds £	Restricted Funds £	Total £
Elimination of inter-company room hire	31,577	-	(31,577)	-
Transfer to building repair fund	(80,000)	80,000	-	-
	<u>(48,423)</u>	<u>80,000</u>	<u>(31,577)</u>	<u>-</u>

15 Analysis of group net assets

	General funds £	Designated funds £	Restricted funds £	Permanent endowment funds £	Total £
Fixed assets	48,325	2,136,227	3,598,308	-	5,782,860
Investments	133,099	-	540,845	1,471,664	2,145,608
Cash on deposit and at bank	394,608	832,180	2,713,934	143,928	4,084,650
Other net current (liabilities)/assets	(46,340)	-	(1,883,682)	-	(1,930,022)
Liabilities due after one year	-	-	(223,530)	-	(223,530)
	<u>529,692</u>	<u>2,968,407</u>	<u>4,745,875</u>	<u>1,615,592</u>	<u>9,859,566</u>

16 Company status and membership

The Academy of Medical Sciences is a registered charity and company limited by guarantee and does not have a share capital. In the event of the company being wound up, the liability of each member is limited to £10. At 31 March 2015 there were 1,121 members.

17 Subsidiary undertakings

The charity has provided a loan facility to the Academy of Medical Sciences Trading Limited of £200,000 in an agreement of 1 April 2010 secured by way of a debenture of the same date. Interest on the loan is payable at a margin above LIBOR and there are flexible terms for repayment of the borrowing. At the balance sheet date £100,000 had been drawn down under the facility and the charity does not intend to recall the loan before 30 June 2016.

The Academy is the sole trustee of the Daniel Turnberg Memorial Fund, a separate charity but treated as part of the Academy for the purposes of registration and accounting under parts 4 and 8 of the Charities Act 2011. The Daniel Turnberg Memorial Fund is shown as a separate endowed fund of the Academy at Note 13 and income arising from the investment of the fund is shown as restricted income in that note.

18 Operating lease commitments

The charity has annual commitments under an operating lease for photocopying equipment as follows:

	2015	2014
2-5 years	<u>3,736</u>	<u>3,736</u>